Organon & Co. (OGN)
Organon & Co. (OGN) from its SEC filings: 2025 revenue $6.2 billion (-3% vs the year before), net margin 3%, free cash flow $538.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $6.2 billion |
| Revenue growth | -3% |
| Net income | $187.0 million |
| Net margin | 3.0% |
| Free cash flow | $538.0 million |
| Diluted EPS | $0.72 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -2% |
| Cash | $1.1 billion |
| Long-term debt | $8.5 billion |
| Share count, 1 year | +1% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.